Tafamidis vs placebo
Withdrawals due to adverse events · people with early‐stage TTR‐FAP
It is very uncertain whether tafamidis changes number of dropouts due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
- Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes onlyRR 1.29 [0.3, 5.54]1 study · 128 participantsVery low